Rolapitant Hydrochloride Hydrate

盐酸罗拉匹坦水合物

Report date: 2022/05/18 17:53:16
NME

Base Information

Drug NameRolapitant Hydrochloride Hydrate
Drug Alias Namerolapitant洛拉匹坦盐酸水合物罗拉吡坦盐酸水合物罗拉匹坦Varubi +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNeurokinin 1 receptor antagonists
TargetsNeurokinin 1 receptor
Therapy Area/IndicationsChemotherapy-induced nausea and vomitingVomitingNausea +[5] 
Global Approved IndicationsVomitingNausea
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2015/09/01
Country/TerritoryUnited StatesEU
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesSchering - Plough SaTesaro IncMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesTersera Therapeutics LlcJiangsu Hengrui Pharmaceutical Group Co Ltd
Inactive CompaniesSchering-PloughTesaro Bio Netherlands BvTesaro Inc +[4] 
Active IndicationsVomitingNausea
Inactive IndicationsChemotherapy-induced nausea and vomitingPostoperative Nausea and VomitingCough

Other Information

ATC CodeA04AD
Related LinksWikipediaDrugBankKEGG